Skip to main content

Table 3 Characteristics of Sickle Cell Disease (SCD) patients, by facility, level of A1c testing, Cerner Health Facts™, 2010–2016

From: Use of large scale EHR data to evaluate A1c utilization among sickle cell disease patients

Baseline characteristics

No. of sickle cell disease patients (%)a

HF cohort

N = 37,151

Adherent

N = 2521

NA-1

N = 15,470

NA-4

N = 776

SCD patients with A1c test**

3927 (11)

0

841 (5)

446 (57)

Gender

    

 Male

16,235 (44)

1119 (44)

7257 (47)

332 (43)

 Female

20,822 (56)

1363 (54)

8193 (53)

444 (57)

Age in years: mean (range)*

30.8 (0–90)

38.6 (1–86)

24.5 (6–46)

51.2 (5–84)

Race

    

 African American**

23,764 (64)

2052 (81)

12,366 (80)

354 (46)

 Asian/Pacific Islander*

401 (1)

16 (0.6)

138 (0.9)

9 (1)

 Biracial*

70 (0.2)

1 (0.04)

49 (0.3)

4 (0.5)

 Caucasian**

8933 (24)

290 (12)

1147 (7)

301 (39)

 Hispanic

169 (0.4)

5 (0.2)

62 (0.4)

6 (0.7)

 Native American*

78 (0.2)

5 (0.2)

15 (0.1)

4 (0.5)

 Other*

3736 (10)

152 (6)

1693 (11)

98 (13)

Diagnosis groups

    

 SC-Thal (WoC)*

850 (2)

59 (2)

454 (3)

12 (2)

 SC-Thal (WC)

298 (0.1)

20 (1)

80 (0.5)

4 (0.5)

 HbSS (u)**

14,712 (40)

1271 (50)

5565 (36)

262 (34)

 HbSS (WoC)**

4914 (14)

414 (16)

4201 (34)

218 (28)

 HbSS (WC)**

7255 (20)

524 (21)

3679 (24)

224 (29)

 HbSC (WoC)*

1194 (3)

61 (2)

810 (5)

7 (1)

 HbSC (WC)*

217 (0.6)

7 (0.3)

113 (0.7)

1 (0.1)

 Other SC (WoC)**

311 (1)

67 (3)

158 (1)

5 (0.6)

 Other SC (WC)**

6874 (19)

91 (4)

225 (1)

15 (2)

  1. SC, sickle cell; Thal, thalassemia; WoC, without crisis; WC, with crisis; u, unspecified
  2. Statistical significance between Adherent, NA-1 and NA-4 cohorts is indicated by *p < 0.05 and **p < 0.001
  3. aSubgroups total to less than 100% of the total cohort due to missing data